173 related articles for article (PubMed ID: 20495481)
21. Anthracycline associated cardiac toxicity in children with malignancies.
Mohta R; Saxena A; Jain Y; Gupta S; Thavaraj V; Narain S; Arya LS
Indian Pediatr; 2002 Jun; 39(6):549-55. PubMed ID: 12084948
[No Abstract] [Full Text] [Related]
22. Pathophysiology of anthracycline- and radiation-associated cardiomyopathies: implications for screening and prevention.
Adams MJ; Lipshultz SE
Pediatr Blood Cancer; 2005 Jun; 44(7):600-6. PubMed ID: 15856486
[TBL] [Abstract][Full Text] [Related]
23. Subclinical cardiotoxicity in childhood cancer survivors exposed to very low dose anthracycline therapy.
Leger K; Slone T; Lemler M; Leonard D; Cochran C; Bowman WP; Bashore L; Winick N
Pediatr Blood Cancer; 2015 Jan; 62(1):123-7. PubMed ID: 25176022
[TBL] [Abstract][Full Text] [Related]
24. Using health-related quality of life measures to predict cardiac function in survivors exposed to anthracyclines.
Ginsberg JP; Cnaan A; Zhao H; Clark BJ; Paridon SM; Chin AJ; Rychik J; Hogarty AN; Barber G; Rutkowski M; Kimball TR; DeLaat C; Steinherz LJ; Silber JH
J Clin Oncol; 2004 Aug; 22(15):3149-55. PubMed ID: 15284267
[TBL] [Abstract][Full Text] [Related]
25. Pretreatment and routine echocardiogram monitoring during chemotherapy for anthracycline-induced cardiotoxicity rarely identifies significant cardiac dysfunction or alters treatment decisions: a 5-year review at a single pediatric oncology center.
Watts RG; George M; Johnson WH
Cancer; 2012 Apr; 118(7):1919-24. PubMed ID: 21882180
[TBL] [Abstract][Full Text] [Related]
26. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis of cardiotoxicity induced by anthracyclines.
Elliott P
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
[TBL] [Abstract][Full Text] [Related]
28. Radiation dose and long term risk of cardiac pathology following radiotherapy and anthracyclin for a childhood cancer.
Guldner L; Haddy N; Pein F; Diallo I; Shamsaldin A; Dahan M; Lebidois J; Merlet P; Villain E; Sidi D; Sakiroglu O; Hartmann O; Leftakopoulos D; de Vathaire F
Radiother Oncol; 2006 Oct; 81(1):47-56. PubMed ID: 16989913
[TBL] [Abstract][Full Text] [Related]
29. Presence of prolonged dispersion of qt intervals in late survivors of childhood anthracycline therapy.
Gupta M; Thaler HT; Friedman D; Steinherz L
Pediatr Hematol Oncol; 2002 Dec; 19(8):533-42. PubMed ID: 12487828
[TBL] [Abstract][Full Text] [Related]
30. Echocardiographic Detection of Cardiac Dysfunction in Childhood Cancer Survivors: How Long Is Screening Required?
Ramjaun A; AlDuhaiby E; Ahmed S; Wang L; Yu E; Nathan PC; Hodgson DC
Pediatr Blood Cancer; 2015 Dec; 62(12):2197-203. PubMed ID: 26146944
[TBL] [Abstract][Full Text] [Related]
31. Valvular abnormalities detected by echocardiography in 5-year survivors of childhood cancer: a long-term follow-up study.
van der Pal HJ; van Dijk IW; Geskus RB; Kok WE; Koolen M; Sieswerda E; Oldenburger F; Koning CC; van Leeuwen FE; Caron HN; Kremer LC; van Dalen EC
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):213-22. PubMed ID: 25442333
[TBL] [Abstract][Full Text] [Related]
32. Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group.
Shankar SM; Marina N; Hudson MM; Hodgson DC; Adams MJ; Landier W; Bhatia S; Meeske K; Chen MH; Kinahan KE; Steinberger J; Rosenthal D;
Pediatrics; 2008 Feb; 121(2):e387-96. PubMed ID: 18187811
[TBL] [Abstract][Full Text] [Related]
33. Monitoring of anthracycline-induced cardiotoxicity.
Jannazzo A; Hoffman J; Lutz M
Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
[TBL] [Abstract][Full Text] [Related]
34. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy.
Pinarli FG; Oğuz A; Tunaoğlu FS; Karadeniz C; Gökçora N; Elbeg S
Pediatr Blood Cancer; 2005 Apr; 44(4):370-7. PubMed ID: 15602715
[TBL] [Abstract][Full Text] [Related]
35. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
van Dalen EC; van den Brug M; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
[TBL] [Abstract][Full Text] [Related]
36. [Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?].
Erlaky H; Tóth K; Szabolcs J; Horváth E; Kemény V; Müller J; Csóka M; Jókúti L; Erdélyi D; Kovács G
Magy Onkol; 2006; 50(1):25-32. PubMed ID: 16617380
[TBL] [Abstract][Full Text] [Related]
37. Managing anthracycline-induced cardiotoxicity: beginning with the end in mind.
Salvatorelli E; Menna P; Minotti G
Future Cardiol; 2015 Jul; 11(4):363-6. PubMed ID: 26239550
[No Abstract] [Full Text] [Related]
38. [Evaluation of late cardiac toxicity of anthracycline in childhood].
Butera G; Piciacchia D; Chessa M; Condoluci C; Tornesello A; Delogu AB; Mastrangelo S; Cipriani A
Minerva Pediatr; 1998 Apr; 50(4):111-9. PubMed ID: 9808963
[TBL] [Abstract][Full Text] [Related]
39. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis.
Pugh TJ; Ballonoff A; Rusthoven KE; McCammon R; Kavanagh B; Newman F; Rabinovitch R
Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):845-9. PubMed ID: 19515509
[TBL] [Abstract][Full Text] [Related]
40. Yield of screening echocardiograms during pediatric follow-up in survivors treated with anthracyclines and cardiotoxic radiation.
Spewak MB; Williamson RS; Mertens AC; Border WL; Meacham LR; Wasilewski-Masker KJ
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27966803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
